Metal Tricarbonyl Complexes for Rapid Renal Excretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current renal tracers, such as 99mTc-MAG3, have suboptimal clearance and are not ideal for estimating renal plasma flow due to impaired renal function, necessitating the development of more effective radiopharmaceutical agents for kidney imaging.
Innovation Solution
The use of substituted iminodiacetic acid ligands and metal tricarbonyl complexes, specifically those containing 99mTc or Re, with fluorine-18 (F18) or other radionuclides, like Re(CO)3(N-(2-fluoroethyl)iminodiacetate, which exhibit rapid renal excretion and clearance comparable to the gold standard 131I-OIH, are employed as renal tracers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 99mTc-MAG3 is used as a renal tracer, then imaging of renal function can be performed, but the clearance is suboptimal (50-65% compared to 131I-OIH) and elimination occurs via the hepatobiliary tract which is exacerbated in patients with impaired renal function
Solution Approach 1:
The patent modifies the chemical structure of iminodiacetic acid ligands by introducing fluorinated alkyl groups at specific positions (alpha, beta, or gamma carbons). This structural parameter change alters the tracer's pharmacokinetic properties, enabling rapid renal excretion comparable to 131I-OIH while maintaining stability and selectivity for renal clearance over hepatobiliary elimination
Solution Approach 2:
The patent creates composite radiopharmaceutical molecules combining 99mTc metal center with modified iminodiacetic acid ligands containing fluorinated groups. This composite structure integrates the diagnostic capabilities of 99mTc with the enhanced renal excretion properties of the fluorinated ligand, achieving both high imaging quality and optimal clearance
2Illumination intensity
If current renal tracers are used, then kidney imaging can be performed, but image quality is compromised due to suboptimal clearance and prolonged circulation time
Solution Approach 1:
By changing the ligand structure to include fluorinated alkyl groups, the patent optimizes the tracer's hydrophilicity and molecular recognition properties, resulting in rapid renal filtration and reduced circulation time. This parameter modification ensures that the tracer clears quickly from blood, improving image quality by reducing background signal while maintaining high target-to-background ratio
3Measurement precision
If 99mTc-MAG3 clearance is relied upon for renal plasma flow estimation, then measurement can be performed, but accuracy is reduced due to hepatobiliary elimination pathway
Solution Approach 1:
The patent introduces fluorinated groups at specific local positions (alpha, beta, or gamma carbons of the iminodiacetic acid ligand) to locally modify the tracer's interaction with renal transport mechanisms. This localized structural modification ensures exclusive renal elimination without activating hepatobiliary pathways, thereby improving measurement precision for renal plasma flow estimation
Data Source
AI summary
This disclosure relates to compositions comprising substituted iminodiacetic acid ligands and metal tricarbonyl complexes containing the ligands and derivatives thereof. In certain embodiments, the metal tricarbonyl complexes are used as radioisotope tracers such as renal tracers. In certain embodiments, the metal complexes comprise 99mTc or Re. In certain embodiments, the ligands are substituted with a fluorine, a fluorine-18(F18) radioisotope, or other radionuclide.